Journal
JOURNAL OF DIABETES INVESTIGATION
Volume 3, Issue 5, Pages 464-467Publisher
WILEY-BLACKWELL
DOI: 10.1111/j.2040-1124.2012.00214.x
Keywords
Dipeptidyl peptidase-4 inhibitor; n-3 Polyunsaturated fatty acid; Type 2 diabetes
Categories
Funding
- Eli Lilly
- MSD
- Sanofi-Aventis
- Takeda
- Novartis
- Japan Diabetes Foundation
- Diabetes Masters Conference
Ask authors/readers for more resources
This study was initiated to identify clinical and dietary parameters that predict efficacy of dipeptidyl peptidase-4 inhibitors. A total of 72 untreated Japanese patients with type 2 diabetes who received DPP-4 inhibitors (sitagliptin, alogliptin or vildagliptin) for 4 months were examined for changes of glycated hemoglobin (HbA1c) and body mass index (BMI), and self-administered 3-day food records, as well as serum levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). DPP-4 inhibitors significantly reduced HbA1c (before initiation of DPP-4 inhibitors 7.2 +/- 0.7%, 4 months after initiation of DPP-4 inhibitors 6.7 +/- 0.6% [paired t-test, P < 0.01 vs before]). Multiple regression analysis showed that changes of HbA1c were significantly correlated with baseline HbA1c, as well as estimated intake of fish. Furthermore, changes of HbA1c were significantly correlated with serum levels of EPA (r = -0.624, P < 0.01) and DHA (r = -0.577, P < 0.01). HbA1c reduction by DPP-4 inhibitors is significantly correlated with estimated intake of fish and serum levels of EPA and DHA. (J Diabetes Invest, doi: 10.1111/j.2040-1124.2012.00214.x, 2012)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available